Ovarian Cancer | Specialty

PARP Combos With Bevacizumab, Immunotherapy in Development for Ovarian Cancer Treatment

February 10th 2018

Rebecca C. Arend, MD, discussed novel combinations being investigated for the treatment of patients with ovarian cancer.

Expert Highlights PARP Inhibitor Advancements in Ovarian Cancer, Points to Future Combos

February 10th 2018

David O'Malley, MD, discusses the excitement surrounding PARP inhibitors for patients with ovarian cancer.

Dr. Moore on Immunotherapy and PARP Combinations in BRCA-Mutated Ovarian Cancer

February 10th 2018

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses combinations of immunotherapy with PARP inhibitors for patients with BRCA-mutated ovarian cancer.

Immunotherapy Combinations Slated to Pave the Way in Ovarian Cancer Treatment

February 9th 2018

Kathleen Moore, MD, discusses combination strategies with immunotherapy for patients with ovarian cancer.

Dr. Al-Niaimi on the Future Role of Cytoreductive Surgery in Ovarian Cancer

February 9th 2018

Ahmed N. Al-Niaimi, MD, assistant professor of obstetrics and gynecology, University of Wisconsin School of Medicine and Public Health, discusses the future role for cytoreductive surgery for the treatment of patients with ovarian cancer.

Dr. Crane on the Impact of PARP Inhibitors in Ovarian Cancer

February 9th 2018

Erin K. Crane, MD, MPH, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses the impact of PARP inhibitors for patients with ovarian cancer.

Dr. Markman on Overall Survival as an Endpoint in Ovarian Cancer Trials

February 7th 2018

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses overall survival as an endpoint in ovarian cancer clinical trials.

Prexasertib Promising in BRCA Wild-Type Ovarian Cancer

February 2nd 2018

Prexasertib (LY2606368) induced a 29% response rate with acceptable tolerability in women with measurable, recurrent high-grade serous or high-grade endometrioid ovarian carcinoma.

Inheritance Matters: The Race to Prevent New Ovarian Cancer Cases

January 31st 2018

Emerging data have confirmed that ovarian cancer is a much more heterogeneous disease than previously recognized.

Biomarkers Go Beyond "All or None" Equation

January 31st 2018

The FDA’s recent approvals of novel anti-PARP agents as maintenance therapy for patients with previously treated advanced ovarian cancer highlight an issue that has received inadequate attention in the peer-reviewed oncology literature.

PARP Inhibition Enhanced Through Combination in Ovarian Cancer

January 27th 2018

Mansoor Raza Mirza, MD, discusses the initial findings and next steps for the promising niraparib plus bevacizumab combination in ovarian cancer, as well as overall advances with PARP inhibitors in the field.

HIPEC Improves Survival in Advanced Ovarian Cancer

January 25th 2018

Adding hyperthermic intraperitoneal chemotherapy to interval cytoreductive surgery improved relapse-free survival and overall survival for women with newly diagnosed stage III epithelial ovarian cancer.

Markman Proposes Shift in Ovarian Cancer Clinical Trial Paradigm

January 16th 2018

Maurie Markman, MD, discusses the need to change the paradigm of clinical trials and FDA approvals in ovarian cancer.

Dr. Sessa on the Management of BRCA1/2 Mutations in Ovarian Cancer

January 11th 2018

Cristiana Sessa, MD, head of Phase I-II Unit and Pharmacology, vice head of Medical Oncology and Head of Clinical Research, Oncology Institute of Southern Switzerland, discusses the management of BRCA1/2 mutations in patients with ovarian cancer.

Dr. Sehouli Discusses Unmet Needs in Ovarian Cancer

January 8th 2018

Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité – Universitatsmedizin Berlin, discusses the unmet needs for patients with ovarian cancer.

Letrozole Maintenance Therapy Improves RFS in Ovarian Cancer

January 4th 2018

Women with ER-positive advanced high-grade serous ovarian cancer assigned to maintenance therapy with letrozole were more likely to be recurrence-free at 24 months.

Dr. Ledermann Discusses Patient Selection in Ovarian Cancer

January 3rd 2018

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses patient selection in the treatment of patients with ovarian cancer.

Targeting Tumor Vasculature in Ovarian Cancer

December 28th 2017

Robert L. Coleman, MD, discusses targeting tumor vasculature and angiogenesis in ovarian cancer.

Unmet Needs in Ovarian Cancer

December 23rd 2017

Evolving Role of PARP Inhibitors in Ovarian Cancer

December 23rd 2017